BlogHeader.png
Syed T. Husain

Syed T. Husain

Recent Posts by Syed T. Husain:

Editorial: Supply Chain Management and the Importance of Security of Supply


As published in Pharma's Almanac Q4 2016.

As global demands rise, supply chains are
becomingly increasingly complex. Of course, with
this increased complexity comes increased risk of
error and, more significantly, increased risk of supply
disruptions and drug shortages. In order to prepare
for the possibility of unforeseen events affecting
the supply chain, contingency plans are a priority.
Alcami’s innovative Protect Your Brand™ is a key
example of this type of security service, offered
through an outsourcing partner.

Topics: Thought Leadership Supply Chain Editorials

Embracing Formulation Expertise to Extend Exclusivity & Improve the Patient Experience


Screen_Shot_2016-09-22_at_3.04.09_PM.pngAs published in Pharma's Almanac Q3 2016.

Offering potential exclusivity and access to larger markets, reformulation efforts can prove extremely valuable to both pharmaceutical and biopharmaceutical manufacturers. With reliable CDMO support, this value can be developed in a cost-effective manner and with minimal inconvenience, while reducing the impact of patent loss.

With considerable room for growth in emerging markets, the surge in biopharmaceutical drug development and approvals, as well as merger and acquisition activities that are helping to further existing expertise, has left the pharmaceuticals market poised for growth. At an expected compounded annual growth rate (CAGR) of 4% to 7%, the market is predicted to reach $1.3 trillion in 2018, but challenges still exist as traditional pharmaceuticals are rapidly approaching or have already reached the patent cliff and biopharmaceuticals are beginning to experience competition from biosimilars. Faced w

Topics: Thought Leadership

Rigorous Integration in a Scalable Development and Manufacturing Enterprise to Support Continued Growth of Biopharmaceuticals


Screen_Shot_2016-09-22_at_3.08.36_PM.pngAs published in Pharma's Almanac Q2 2016.


The pharmaceutical and biopharmaceutical development and manufacturing market continue to experience significant expansion as the development of small molecule drugs and more complex large-molecule biologics rival for attention. Small and midsize pharma/biotech companies
are leading drug discovery and the engagement 
of contract development and manufacturing organizations (CDMOs) helps them to improve capabilities and enable companies to compete 
in this dynamic market.

Topics: Thought Leadership

Strengthening CDMOs to Meet Industry Needs For 2016 And Beyond

SStrengthening_CDMOs.png

As published in Pharma's Almanac Q1 2016.

Outsourcing companies pursuing an integrated services model aim to facilitate drug development and commercialization for drug sponsors by enabling them to work with a single partner for activities that often require multiple, specialized vendors.

With a single qualified partner, pharma companies can have simplified access to integrated analytical, devel- opment, manufacturing and packaging services, as well as a broad range of dose form manufacturing and simi- lar services. Some contract development and manufac- turing organizations (CDMOs) offer both API and drug product manufacture, while others offer formulation development and clinical supply manufacture to com- plement their commercial production operations. Re- gardless, the aim is to provide a seamless supply chain solution.

Topics: Thought Leadership

Bolstering Capabilities For Parenteral Drug Development and Manufacturing

Bolstering_Cap_Parenteral_Drug_Dev.png

As published in Pharma's Almanac Q4 2015.

ABSTRACT

As the pharmaceutical and biotechnology markets undergo significant changes, companies are relying more heavily on CROs and CMOs to provide the needed services, expertise, and technologies to help them favorably compete in a challenging marketplace. Contract service providers, in turn, are strengthen- ing their capabilities to satisfy current demands, in some cases by coming together. An example is the recent combining of AAIPharma and Cambridge Major Laboratories, forming a full-service global CDMO supplying drug substance and drug product development, manufacturing, testing, and packaging services. This coupling also supports drug sponsors facing the escalating challenges of developing and manufacturing parenteral drug products.

Topics: Thought Leadership